generic competition news from FiercePharma
News
GSK accused of monopolizing Wellbutrin
Did GlaxoSmithKline try to monopolize the Wellbutrin market? A lawsuit now certified as class-action says so. The plaintiffs accuse GSK of artificially boosting Wellbutrin prices by fibbing to the Read more...
AZ stock falls on Symbicort patent loss
What a difference one patent ruling can make. AstraZeneca lost almost $1.3 billion in market value today after announcing that the European Patent Office yanked a patent covering its blockbuster Read more...
Make generic-switching bonuses illegal?
Should insurers be allowed to reward docs who switch patients to generics? That debate is going public in Colorado, where legislators have proposed a bill that would prohibit the practice. On the Read more...
Drugmakers resist U.K. price goals
Drug companies are standing their ground in price negotiations with the U.K. government. Pharma is offering to cut the U.K.'s drug bill by roughly half the government's goal, The Daily Telegraph Read more...
Could Clarinex be vulnerable to generics?
Consider this scenario from Fred Hassan's nightmares: The $800 million Clarinex, ostensibly under patent till 2020, Read more...
Wyeth to slash another 1,200 jobs
And the ax is falling again. Wyeth notified employees last Friday than another 1,200 jobs will be slashed from the payroll. That's on top of the Read more...
Under pharma earnings, basic problems
You've heard of see-through buildings. How about see-through pharma earnings? Though drug makers have been reporting increases to their bottom lines, investors are looking past the foreign-currency Read more...
Wyeth discounts Pristiq for big sales push
Think the latest-and-greatest drug would naturally be the most expensive? Think again. Now that its Pristiq antidepressant is Read more...
New CEO expected to'strip' Biovail
To listen to news reports about incoming Biovail CEO Bill Wells, you'd think he was one of the horsemen of the Apocalypse. A director for three years, Wells is set to take over the helm May 1, and Read more...
Roche, Cipla trade jabs on Tarceva
We turn to India for updates on another cancer-drug battle, this one between Roche's brand-name Tarceva and Cipla's copycat version, Erlocip. A Roche distributor tattled to India's Drug Controller Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight